Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: A meta-analysis

Molecular Psychiatry

Volumn 19, Issue 8, 2014, Pages 880-889

  Faraone, S V ^a   Spencer, T J ^b   Madras, B K ^c   Zhang James, Y ^a   Biederman, J ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ADHD; dopamine transporter; genetics; meta analysis; PET; SPECT

Indexed keywords

DOPAMINE TRANSPORTER;

3' UNTRANSLATED REGION; ARTICLE; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IN VIVO STUDY; INFORMATION RETRIEVAL; MENTAL DISEASE; META ANALYSIS (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; VARIABLE NUMBER OF TANDEM REPEAT; ADOLESCENT; ADULT; AGED; ALLELE; FUNCTIONAL NEUROIMAGING; GENETICS; META ANALYSIS; METABOLISM; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT; NEUROIMAGING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FUNCTIONAL NEUROIMAGING; GENOTYPE; HUMANS; MIDDLE AGED; MINISATELLITE REPEATS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 84905036855     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.126     Document Type: Article

References (91)

1. Brookes KJ, Xu X, Anney R, Franke B, Zhou K, Chen W et al. Association of ADHD with genetic variants in the 5'-region of the dopamine transporter gene: Evidence for allelic heterogeneity. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1519-1523.
2. Asherson P, Brookes K, Franke B, Chen W, Gill M, Ebstein RP et al. Confirmation that a specific haplotype of the dopamine transporter gene is associated with combined-Type ADHD. Am J Psychiatry 2007; 164: 674-677. (Pubitemid 46650201)
3. Roessner V, Sagvolden T, Dasbanerjee T, Middleton FA, Faraone SV, Walaas SI et al. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type. Neuroscience 2011; 167: 1183-1191.
4. Mick E, Kim JW, Biederman J, Wozniak J, Wilens T, Spencer T et al. Family based association study of pediatric bipolar disorder and the dopamine transporter gene (SLC6A3). Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1182-1185.
5. Tarnok Z, Ronai Z, Gervai J, Kereszturi E, Gadoros J, Sasvari-Szekely M et al. Dopaminergic candidate genes in Tourette syndrome: Association between tic severity and 3'UTR polymorphism of the dopamine transporter gene. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 900-905. (Pubitemid 47547991)
6. Du Y, Nie Y, Li Y, Wan YJ. The association between the SLC6A3 VNTR 9-repeat allele and alcoholism-A meta-Analysis. Alcohol Clin Exp Res 2011; 35: 1625-1634.
7. Gamma F, Faraone SV, Glatt SJ, Yeh YC, Tsuang MT. Meta-Analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene. Schizophr Res 2005; 73: 55-58. (Pubitemid 39574679)
8. Faraone SV, Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am 2010; 33: 159-180.
9. Franke B, Vasquez AA, Johansson S, Hoogman M, Romanos J, Boreatti-Hummer A et al. Multicenter analysis of the SLC6A3/DAT1 VNTR haplotype in persistent ADHD suggests differential involvement of the gene in childhood and persistent ADHD. Neuropsychopharmacology 2010; 35: 656-664.
10. Kuczenski R, Segal DS. Exposure of adolescent rats to oral methylphenidate: Preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 2002; 22: 7264-7271.
11. Segal DS, Kuczenski R. Repeated binge exposures to amphetamine and methamphetamine: Behavioral and neurochemical characterization. J Pharmacol Exp Ther 1997; 282: 561-573. (Pubitemid 27340153)
12. Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: New model on its therapeutic actions for attention-deficit/ hyperactivity disorder. Biol Psychiatry 2005; 57: 1410-1415. (Pubitemid 40798562)
13. Riccardi P, Baldwin R, Salomon R, Anderson S, Ansari MS, Li R et al. Estimation of baseline dopamine D(2) receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [(18)F] Fallypride. Biol Psychiatry 2008; 63: 241-244. (Pubitemid 350299319)
14. Spencer T, Biederman J, Ciccone P, Madras B, Dougherty D, Bonab A et al. A PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short and long-Acting orally administered formulations of methylphenidate in adults. Am J Psychiatry 2006; 163: 387-395. (Pubitemid 44469379)
15. Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopamine transporter alterations in ADHD: Pathophysiology or adaptation to psychostimulants?. A metaanalysis. Am J Psychiatry 2012; 169: 264-272.
16. Spencer TJ, Madras BK, Fischman AJ, Krause J, La Fougere C. Striatal dopamine transporter binding in adults with ADHD. Am J Psychiatry 2012; 169: 665 author reply 6.
17. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 2001; 1: 152-156. (Pubitemid 33757602)
18. Van Ness SH, Owens MJ, Kilts CD. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 2005; 6: 55.
19. Mill J, Asherson P, Craig I, D'Souza UM. Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet 2005; 6: 3.
20. Greenwood TA, Kelsoe JR. Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 2003; 82: 511-520. (Pubitemid 37239027)
21. Inoue-Murayama M, Adachi S, Mishima N, Mitani H, Takenaka O, Terao K et al. Variation of variable number of tandem repeat sequences in the 3'-untranslated region of primate dopamine transporter genes that affects reporter gene expression. Neurosci Lett 2002; 334: 206-210. (Pubitemid 35350858)
22. Brookes KJ, Neale BM, Sugden K, Khan N, Asherson P, D'Souza UM. Relationship between VNTR polymorphisms of the human dopamine transporter gene and expressionin post-mortem midbrain tissue. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1070-1078. (Pubitemid 350207783)
23. Pinsonneault JK, Han DD, Burdick KE, Kataki M, Bertolino A, Malhotra AK et al. Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology 2011; 36: 1644-1655.
24. Zhou Y, Michelhaugh SK, Schmidt CJ, Liu JS, Bannon MJ, Lin Z. Ventral midbrain correlation between genetic variation and expression of the dopamine transporter gene in cocaine-Abusing versus non-Abusing subjects. Addict Biol advance online publication, 26 October 2011; doi:10.1111/j.1369-1600.2011.00391. x (e-pub ahead of print).
25. Mill J, Asherson P, Browes C, D'Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3'UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 2002; 114: 975-979. (Pubitemid 35379243)
26. Brown AB, Biederman J, Valera EM, Doyle AE, Bush G, Spencer T et al. Effect of dopamine transporter gene (SLC6A3) variation on dorsal anterior cingulate function in attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 365-375.
27. Paloyelis Y, Asherson P, Mehta MA, Faraone SV, Kuntsi J. DAT1 and COMT effects on delay discounting and trait impulsivity in male adolescents with attention deficit/hyperactivity disorder and healthy controls. Neuropsychopharmacology 2010; 35: 2414-2426.
28. Scherk H, Backens M, Schneider-Axmann T, Kraft S, Kemmer C, Usher J et al. Dopamine transporter genotype influences N-Acetyl-Aspartate in the left putamen. World J Biol Psychiatry 2009; 10(4 Pt 2): 524-530.
29. Rommelse NN, Altink ME, Arias-Vasquez A, Buschgens CJ, Fliers E, Faraone SV et al. A review and analysis of the relationship between neuropsychological measures and DAT1 in ADHD. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1536-1546.
30. Shumay E, Chen J, Fowler JS, Volkow ND. Genotype and ancestry modulate brain's DAT availability in healthy humans. PLoS One 2011; 6: E22754.
31. Spencer TJ, Biederman J, Faraone SV, Madras BK, Bonab AA, Dougherty DD et al. Functional genomics of attention-deficit/hyperactivity disorder (ADHD) Risk alleles on dopamine transporter binding in ADHD and healthy control subjects. Biol Psychiatry 2012.
32. Costa A, Riedel M, Muller U, Moller HJ, Ettinger U. Relationship between SLC6A3 genotype and striatal dopamine transporter availability: A meta-Analysis of human single photon emission computed tomography studies. Synapse 2011; 65: 998-1005.
33. Lynch WJ, Roth ME, Carroll ME. Biological basis of sex differences in drug abuse: Preclinical and clinical studies. Psychopharmacology 2002; 164: 121-137. (Pubitemid 36015575)
34. Cheon KA, Ryu YH, Kim JW, Cho DY. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: Relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 2005; 15: 95-101.
35. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-Analyses. BMJ 2003; 327: 557-560. (Pubitemid 37088507)
37. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Academic Press: Orlando, 1985, p 369 ill.; 24 cm. p.
38. Hunter JE, Schmidt FL. Methods of Neta-Analysis: Correcting Error and Bias in Research Findings. Sage Publications: Newbury Park, CA, 1990, p 592.
39. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-634. (Pubitemid 27387172)
40. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 2005; 46: 745-751.
41. Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB et al. Prediction of dopamine transporter binding availability by genotype: A preliminary report. Am J Psychiatry 2000; 157: 1700-1703.
42. Martinez D, Gelernter J, Abi-Dargham A, van Dyck CH, Kegeles L, Innis RB et al. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 2001; 24: 553-560. (Pubitemid 32248685)
43. Lynch DR, Mozley PD, Sokol S, Maas NM, Balcer LJ, Siderowf AD. Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease. Mov Disord 2003; 18: 804-812. (Pubitemid 36939976)
44. Kaufman MJ, Madras BK. Distribution of cocaine recognition sites in monkey brain: II. Ex vivo autoradiography with [3H]CFT and [125I]RTI-55. Synapse 1992; 12: 99-111.
45. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/ hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 2005; 57: 229-238. (Pubitemid 40187366)
46. Madras BK, Gracz LM, Fahey MA, Elmaleh D, Meltzer PC, Liang AY et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse 1998; 29: 116-127. (Pubitemid 28221790)
47. Fischman AJ, Bonab AA, Babich JW, Palmer EP, Alpert NM, Elmaleh DR et al. Rapid detection of Parkinson's disease by SPECT with altropane: A selective ligand for dopamine transporters. Synapse 1998; 29: 128-141. (Pubitemid 28221791)
48. Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 1996; 37: 1129-1133. (Pubitemid 26329519)
49. Mozley PD, Kim HJ, Gur RC, Tatsch K, Muenz LR, McElgin WT et al. Iodine-123-IPT SPECT imaging of CNS dopamine transporters: Nonlinear effects of normal aging on striatal uptake values. J Nucl Med 1996; 37: 1965-1970. (Pubitemid 26428363)
50. Kung MP, Stevenson DA, Plossl K, Meegalla SK, Beckwith A, Essman WD et al. [99mTc]TRODAT-1: A novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med 1997; 24: 372-380. (Pubitemid 27183040)
51. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K, Ackenheil M. Stimulantlike action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. Int J Neuropsychopharmacol 2002; 5: 111-113. (Pubitemid 34662972)
52. D'Souza UM, Craig IW. Functional polymorphisms in dopamine and serotonin pathway genes. Hum Mutat 2006; 27: 1-13. (Pubitemid 43045703)
53. Hahn MK, Blakely RD. The functional impact of SLC6 transporter genetic variation. Annu Rev Pharmacol Toxicol 2007; 47: 401-441. (Pubitemid 46277034)
54. Sanyal A, Lajoie BR, Jain G, Dekker J. The long-range interaction landscape of gene promoters. Nature 2012; 489: 109-113.
55. Miller GM, Madras BK. Polymorphisms in the 30-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry 2002; 7: 44-55. (Pubitemid 34087878)
56. Michelhaugh SK, Fiskerstrand C, Lovejoy E, Bannon MJ, Quinn JP. The dopamine transporter gene (SLC6A3) variable number of tandem repeats domain enhances transcription in dopamine neurons. J Neurochem 2001; 79: 1033-1038. (Pubitemid 33117083)
57. D'Souza UM, Russ C, Tahir E, Mill J, McGuffin P, Asherson PJ et al. Functional effects of a tandem duplication polymorphism in the 5'flanking region of the DRD4 gene. Biol Psychiatry 2004; 56: 691-697. (Pubitemid 39446852)
58. Paloyelis Y, Mehta MA, Faraone SV, Asherson P, Kuntsi J. Striatal sensitivity during reward processing in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012; 51: 722-32 e9.
59. Hoogman M, Onnink M, Cools R, Aarts E, Kan C, Arias Vasquez A et al. The dopamine transporter haplotype and reward-related striatal responses in adult ADHD. Eur Neuropsychopharmacol 2013; 23: 469-478.
60. Franke B, Hoogman M, Arias Vasquez A, Heister JG, Savelkoul PJ, Naber M et al. Association of the dopamine transporter (SLC6A3/DAT1) gene 9-6 haplotype with adult ADHD. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1576-1579.
61. Loder MK, Melikian HE. The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J Biol Chem 2003; 278: 22168-22174. (Pubitemid 36792628)
62. Lasky-Su J, Neale BM, Franke B, Anney RJ, Zhou K, Maller JB et al. Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1345-1354.
63. Lasky-Su J, Anney RJ, Neale BM, Franke B, Zhou K, Maller JB et al. Genome-wide association scan of the time to onset of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1355-1358.
64. Markunas CA, Quinn KS, Collins AL, Garrett ME, Lachiewicz AM, Sommer JL et al. Genetic variants in SLC9A9 are associated with measures of attention-deficit/ hyperactivity disorder symptoms in families. Psychiatr Genet 2010; 20: 73-81.
65. Franke B, Neale BM, Faraone SV. Genome-wide association studies in ADHD. Hum Genet 2009; 126: 13-50.
66. Mick E, Todorov A, Smalley S, Hu X, Loo S, Todd RD et al. Family-based genomewide association scan of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2010; 49: 898-905 e3.
67. de Silva MG, Elliott K, Dahl HH, Fitzpatrick E, Wilcox S, Delatycki M et al. Disruption of a novel member of a sodium/hydrogen exchanger family and DOCK3 is associated with an attention deficit hyperactivity disorder-like phenotype. J Med Genet 2003; 40: 733-740. (Pubitemid 37311071)
68. Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS et al. Identifying autism loci and genes by tracing recent shared ancestry. Science 2008; 321: 218-223. (Pubitemid 351989087)
69. Neale BM, Medland SE, Ripke S, Asherson P, Franke B, Lesch KP et al. Meta-Analysis of genome-wide association studies of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2010; 49: 884-897.
70. Zhang-James Y, Dasbanerjee T, Sagvolden T, Middleton FA, Faraone SV. SLC9A9 mutations, gene expression, and protein-protein interactions in rat models of attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2011; 156: 835-843.
71. Zhang-James Y, Middleton FA, Sagvolden T, Faraone SV. Differential expression of SLC9A9 and interacting molecules in the hippocampus of rat models for attention deficit/hyperactivity disorder. Dev Neurosci 2012; 34: 218-227.
72. Methner DN, Mayfield RD. Ethanol alters endosomal recycling of human dopamine transporters. J Biol Chem 2010; 285: 10310-10317.
73. Pandolfo P, Machado NJ, Kofalvi A, Takahashi RN, Cunha RA. Caffeine regulates frontocorticostriatal dopamine transporter density and improves attention and cognitive deficits in an animal model of attention deficit hyperactivity disorder. Eur Neuropsychopharmacol 2013; 23: 317-328.
74. Roessner V, Sagvolden T, Dasbanerjee T, Middleton FA, Faraone SV, Walaas SI et al. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type. Neuroscience 2010; 167: 1183-1191.
75. Krause J, Dresel SH, Krause KH, La Fougere C, Zill P, Ackenheil M. Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: No higher DAT availability in patients with homozygosity for the 10-repeat allele. World J Biol Psychiatry 2006; 7: 152-157. (Pubitemid 44132540)
76. Sanchez-Mora C, Ribases M, Casas M, Bayes M, Bosch R, Fernandez-Castillo N et al. Exploring DRD4 and its interaction with SLC6A3 as possible risk factors for adult ADHD: A meta-Analysis in four European populations. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 600-612.
77. Hawi Z, Kent L, Hill M, Anney RJ, Brookes KJ, Barry E et al. ADHD and DAT1: Further evidence of paternal over-Transmission of risk alleles and haplotype. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 97-102.
78. Altink ME, Slaats-Willemse DI, Rommelse NN, Buschgens CJ, Fliers EA, Arias-Vasquez A et al. Effects of maternal and paternal smoking on attentional control in children with and without ADHD. Eur Child Adolesc Psychiatry 2009; 18: 465-475.
79. Guindalini C, Martins RC, Andersen ML, Tufik S. Influence of genotype on dopamine transporter availability in human striatum and sleep architecture. Psychiatry Res 2010; 179: 238-240.
80. Shumay E, Fowler JS, Volkow ND. Genomic features of the human dopamine transporter gene and its potential epigenetic states: Implications for phenotypic diversity. PLoS One 2010; 5: E11067.
81. Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW et al. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 1999; 409: 38-56. (Pubitemid 29242784)
82. Cruz-Muros I, Afonso-Oramas D, Abreu P, Perez-Delgado MM, Rodriguez M, Gonzalez-Hernandez T. Aging effects on the dopamine transporter expression and compensatory mechanisms. Neurobiol Aging 2009; 30: 973-986.
83. Tani S, Kuraku S, Sakamoto H, Inoue K, Kusakabe R. Developmental expression and evolution of muscle-specific microRNAs conserved in vertebrates. Evol Dev 2013; 15: 293-304.
84. Lee I, Ajay SS, Yook JI, Kim HS, Hong SH, Kim NH et al. New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. Genome Res 2009; 19: 1175-1183.
85. Drgon T, Lin Z, Wang GJ, Fowler J, Pablo J, Mash DC et al. Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol 2006; 26: 875-889.
86. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H et al. Systematic localization of common disease-Associated variation in regulatory DNA. Science 2012; 337: 1190-1195.
87. Contin M, Martinelli P, Mochi M, Albani F, Riva R, Scaglione C et al. Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease. Clin Neuropharmacol 2004; 27: 111-115. (Pubitemid 38746009)
88. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000; 22: 133-139. (Pubitemid 30016015)
89. Gunnar MR, Brodersen L, Krueger K, Rigatuso J. Dampening of adrenocortical responses during infancy: Normative changes and individual differences. Child Dev 1996; 67: 877-889. (Pubitemid 126418129)
90. Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gasso P et al. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophr Res 2007; 90: 115-122. (Pubitemid 46177550)
91. van de, Giessen E, de Win MM, Tanck MW, van den Brink W, Baas F et al. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med 2009; 50: 45-52.